Abstract Summary
Objective
To assess the evidence from clinical trials, animal studies, and mechanistic research examining the lipid-lowering potential of ashwagandha (Withania somnifera) supplementation, with specific attention to its effects on total cholesterol, LDL-c, HDL-c, VLDL-c, and triglycerides.
Context
Dyslipidemia — characterized by elevated LDL cholesterol, reduced HDL cholesterol, and high triglycerides — is a major modifiable risk factor for cardiovascular disease. Overweight and obesity are frequently linked to dyslipidemia and heightened cardiovascular risk, and the search for safe and effective complementary treatments has promoted growing interest in natural supplements such as ashwagandha, recognized for its adaptogenic and potential lipid-lowering properties. Ashwagandha has been used for centuries in Ayurvedic medicine as a rasayana, or rejuvenating herb. Its active compound, withaferin A, has attracted scientific interest for its role in modulating lipid metabolism pathways. As cardiovascular disease remains a leading global health burden, the potential of herbal compounds to complement conventional lipid management strategies has become increasingly relevant.
Methods Used
Approach
Peer-reviewed randomized controlled trials (RCTs), double-blind placebo-controlled pilot studies, preclinical animal studies, in vitro analyses, and systematic narrative reviews examining the effects of ashwagandha supplementation on serum lipid concentrations were analyzed. Studies were selected based on measurable biochemical outcomes related to lipid profiles.
Data Collection
Data included changes in serum total cholesterol, LDL-c, HDL-c, VLDL-c, and triglyceride concentrations, as well as anthropometric parameters. A 40-day double-blind, randomized, placebo-controlled pilot clinical trial involving 43 adults administered one daily capsule containing 500 mg of ashwagandha or a placebo, alongside a guided dietary plan, with biochemical measurements taken at baseline and after the intervention. Additional data were drawn from escalating-dose volunteer studies and animal models using induced hypercholesterolemia.
Researchers' Summary of Findings
Impact on Health
Small-scale clinical trials have shown that ashwagandha root extract may help reduce total cholesterol, LDL, and triglycerides in individuals with mild to moderate hypercholesterolemia. A randomized controlled trial published in 2012 found significant reductions in total cholesterol and LDL after 60 days of supplementation. A separate exploratory study using escalating doses of 750 to 1,250 mg per day also noted a significant reduction in total cholesterol and a gradual decreasing trend in triglycerides, with no adverse effects on organ function.
At the mechanistic level, withaferin A has been found to contribute to lipid homeostasis by activating the sodium-dependent transporter Asbt, which plays a role in transporting bile acids and enhancing the emulsification of lipids for proper absorption. Animal studies involving induced dyslipidemia demonstrated significant reductions in triglycerides, LDL-c, and VLDL-c, while simultaneously increasing HDL-c levels. The accumulated preclinical and clinical evidence highlights ashwagandha's multifaceted role in lipid metabolism, including anti-adipogenic properties, enhancement of energy expenditure, and protective effects against oxidative stress and inflammation.
Health Implications
Despite these promising results, the overall quality and quantity of evidence remains limited. Most clinical studies have small sample sizes, short durations, and sometimes lack rigorous controls. Larger, well-designed trials are needed to confirm these effects and establish optimal dosing and long-term safety guidelines. Individuals with diagnosed hypercholesterolemia should not replace physician-directed treatment with ashwagandha supplementation without medical consultation, and those on lipid-lowering medications should seek professional guidance before adding this herb to their regimen.
Sustainability
The reductions in LDL-c/HDL-c ratio, VLDL-c, and triglycerides observed in intervention groups across multiple studies align with in vivo trials targeting the anti-hypolipidemic effects of ashwagandha. For individuals seeking to support cardiovascular health through natural means, ashwagandha may serve as a complementary strategy alongside a heart-healthy diet and regular physical activity. Typical dosages studied in lipid-related trials range from 300 to 600 mg of standardized root extract per day, taken consistently for a minimum of 30 to 60 days to observe measurable changes in lipid markers.
DOI: 10.1186/s12986-025-01028-6
